Signalling pathways that mediate skeletal muscle hypertrophy and atrophy

Nature Cell Biology

Volumn 5, Issue 2, 2003, Pages 87-90

  Glass, David J ^a  

^a REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CALCINEURIN; CALCINEURIN INHIBITOR; CALMODULIN; CLENBUTEROL; CYCLOSPORIN A; DEXAMETHASONE; FK 506 BINDING PROTEIN; GLUCOCORTICOID; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3; INSULIN RECEPTOR SUBSTRATE 1; LIPID; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE; PROTEASOME INHIBITOR; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; RAPAMYCIN; RAS PROTEIN; S6 KINASE; SOMATOMEDIN C; TRANSCRIPTION FACTOR NFAT; UBIQUITIN PROTEIN LIGASE; UNINDEXED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANCER; DRUG EFFICACY; DRUG TARGETING; GENE OVEREXPRESSION; GENE THERAPY; GENETIC TRANSCRIPTION; GLUCOSE TRANSPORT; HUMAN; MOUSE; MUSCLE ATROPHY; MUSCLE DISEASE; MUSCLE HYPERTROPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN INDUCTION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; TREATMENT OUTCOME;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CALCINEURIN; HUMANS; HYPERTROPHY; INSULIN-LIKE GROWTH FACTOR I; LIGASES; MUSCLE PROTEINS; MUSCLE, SKELETAL; MUSCULAR ATROPHY; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ADRENERGIC, BETA-2; SIGNAL TRANSDUCTION; SKP CULLIN F-BOX PROTEIN LIGASES; UBIQUITIN-PROTEIN LIGASES;

EID: 0037318822     PISSN: 14657392     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncb0203-87     Document Type: Review

References (52)

1. Jagoe, R.T. & Goldberg, A.L. What do we really know about the ubiquitin-proteasome pathway in muscle atrophy? Curr. Opin. Clin. Nutr. Care 4, 183-190 (2001).
2. Mosoni, L. et al. Lower recover of muscle protein lost during starvation in old rats despite a stimulation of protein synthesis. Am. J. Physiol. Endocrinol. Metab. 277, E608-616 (1999).
3. Musaro, A. et al. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nature Genet. 27, 195-200 (2001).
4. Mitch, W.E. & Golberg, A.L. Mechanisms of muscle wasting - the role of the ubiquitin-proteasome pathway. N. Engl. J. Med. 335, 1897-1905 (1996).
5. Tawa, N.E. Jr, Odessey, R & Golberg, A.L. Inhibitors of the proteasome reduce the accelerated proteolysis in atrophying rat skeletal muscles. J. Clin. Invest. 100, 197-203 (1997).
6. Goldspink, D.F., Garlick, P.J. & McNurlan, M.A. Protein turnover measure in vivo and in nitro in muscles undergoing compensatory growth and subsequent denervation atrophy. Biochem. J. 210, 89-98 (1983).
7. DeVol, D.L., Rotwein, P., Sadow, J.L., Novakofski, & Bechtel P.J. Activation of insulin-like growth factor gene expression during work-induced skeletal muscle growth. Am. J. Physiol. 259, E89-E95 (1990).
8. Coleman, M.E. et al. Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofibre hypertrophy in transgenic mice. J. Biol. Chem. 270, 12109-12116 (1995).
9. Musaro, A., McCullagh, K. J., Naya, F. J., Olson, E.N. & Rosenthal, N. IGH-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1 Nature 400, 581-585 (1999).
10. Semsarian, C. et al. Skeletal muscle hypertrophy is mediated by a calcium-dependent calcineurin signalling pathway. Nature 400, 576-581 (1999).
11. Dunn, S. E., Burns, J. L. & Michel, R. N. Calcineurin is required for skeletal muscle hypertrophy. J. Biol. Chem. 274, 21908-21912 (1999).
12. Bodine, S. C. et al. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nature Cell Biol. 3, 1014-1019 (2001).
13. Rommel, C. et al. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nature Cell Biol. 3, 1009-1013 (2001).
14. Horsley, V. & Pavlath, G. K. Nfat: ubiquitous regulator of cell differentiation and adaptation. J. Cell Biol. 156, 771-774 (2002).
15. Molkentin, J.D. et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93, 215-228 (1998).
16. Serrano, A.L. et al. Calcineurin controls nerve activity-dependent specification of slow skeletal muscle fibres but not muscle growth. Proc. Natl Acad. Sci. USA 98, 13108-13113 (2001).
17. Dupont-Versteegden, E. E., Knox, M., Gurley, C. M., Houle, J. D. & Peterson, C. A. Maintenance of muscle mass is not dependent on the calcineurin-NFAT pathway. Am. J. Physiol. Cell Physiol. 282, C1387-C1395 (2002).
18. Naya, F. J. et al. Stimulation of slow skeletal muscle fibre gene expression by calcineurin in vivo. J. Biol. Chem. 275, 4545-4548 (2000).
19. Dunn, S. E., Chin, E. R. & Michel, R. N. Matching of calcineurin activity to upstream effectors is critical for skeletal muscle fibre growth. J. Cell Biol. 151, 663-672 (2000).
20. Murgia, M. et al. Ras is involved in nerve-activity-dependent regulation of muscle genes. Nature Cell Biol. 2, 142-147 (2000).
21. Vivanco, I. & Sawyers, C. L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nature Rev. Cancer 2, 489-501 (2002).
22. Takahashi, A. et al. Myogenic Akt signalling regulates blood vessel recruitment during myofibre growth. Mol. Cell Biol. 22, 4803-4814 (2002).
23. Pallafacchina, G., Calabria, E., Serrano, A. L., Kalhovde, J. M. & Schiaffino, S. A protein kinase B-dependent and rapamycin-sensitive pathway controls skeletal muscle growth but not fibre type specification. Proc. Natl Acad. Sci. USA 99, 9213-9218 (2002).
24. Chen, W.S. et al. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev. 15, 2203-2208 (2001).
25. Cho, H. et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB β). Science 292, 1728-1731 (2001).
26. Stambolic, V. et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95, 29-39 (1998).
27. Goberdhan, D. C., Paricio, N., Goodman, E. C., Mlodzik, M. & Wilson , C. Drosophila tumor suppressor PTEN controls cell size and number by antagonizing the Chico/P13-kinase signalling pathway. Genes Dev. 13, 3244-3258 (1999).
28. Huang, H. et al. PTEN affects cell size, cell proliferation and apoptosis dudring Drosophila eye development. Development 126, 5365-5372 (1999).
29. Wada, T. et al. Overexpression of SH2-containing inositol phosphatase 2 results in negative regulation of insulin-induced metabolic actions in 3T3L1 adipocytes via its 5′-phosphatase catalytic activity. Mol. Cell. Biol. 21, 1633-1646 (2001).
30. Stiles, B. et al. Essential role of Akt-1/Protein kinase Bα in PTEN-controlled tumorigenesis. Mol. Cell. Biol. 22, 3842-3851 (2002).
31. Clement, S. et al. The lipid phosphatase SHIP2 controls insulin sensitivity. Nature 409, 92-97 (2001).
32. Leevers, S. J., Weinkove, D., MacDougall, L. K., Hafen, E. & Waterfield, M. D. The Drosophila phosphoinositide 3-kinase Dp110 promotes cell growth. EMBO J. 15, 6584-6594 (1996).
33. Zhang, H., Stallock, J. P., Ng, J. C., Reinhard, C. & Neufeld, T. P. Regulation of cellular growth by the Drosophila target of rapamycin dTOR. Genes Dev. 14, 2712-2724 (2000).
34. Montagne, J. et al. Drosophila S6 kinase: a regulator of cell size. Science 285, 2126-2129 (1999).
35. s6k by PDK1. Science 279, 707-710 (1998).
36. Nave, B. T., Ouwens, M., Withers, D. J., Alessi, D. R. & Shepherd, P. R. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem. J. 344, 427-431 (1999).
37. Scott, P. H., Brunn, G. J., Kohn, A. D., Roth, R. A. and Lawrence J. C. Jr Evidence of insulin-stimulated phosphorylation and activation of the mammalian target of rapamycin mediated by a protein kinase B signalling pathway. Proc. Natl Acad. Sci. USA 95, 77772-7777 (1998).
38. Reynolds, T. H. t., Bodine, S. C. & Lawrence, J. C. Jr. Control of Ser 2448 phosphorylation in the mammalian target of rapamycin by insulin and skeletal muscle load. J. Biol. Chem. 277, 17657-17662 (2002).
39. Inoki, K., Li, Y., Zhu, T., Wu, J. & Guan, K. L. TSC2 is phosphorylated and inhibited by Akt and suppression mTOR signalling. Nature Cell Biol. 4, 648-657 (2002).
40. Tee, A. R. et al. Tuberous sclerosis complex-1 and -2 gene products function together to inhibition mammalian target of rapamycin (mTOR)-mediated downstream signalling. Proc. Natl Acad. Sci. USA 99, 13571-13576 (2002).
41. s6k pathway and is independent of mitogen-activated protein kinase. Proc. Natl Acad. Sci. USA 93, 4076-4080 (1996).
42. Hara, K. et al. Regulation of eIF-4E BP1 phosphorylation by mTOR. J. Biol. Chem. 272, 26457-26463 (1997).
43. Miron, M. et al. The translation inhibitor 4E-BP is an effector pf PI(3)K/Akt signalling and cell growth in Drosophila Nature Cell Biol. 3, 596-601 (2001).
44. Cross, D. A., Alessi, D. R., Cohen, P., Andjelkovich, M. & Hemmings, B.A. Inhibition of glycogen synthase kinase-3 by insulin mediate by protein kinase B. Nature 378, 785-789 (1995).
45. Hinkle, R. T. et al. Skeletal muscle hypertrophy and anti-atrophy effects of clenbuterol are mediated by the β2-adrenergic receptor. Muscle Nerve 25, 729-734 (2002).
46. Crespo, P., Xu, N., Simonds, W. F. & Gutkind, J. S. Ras-dependent activation of MAP kinase pathway mediated by G-protein βγ subunits. Nature 369, 418-420 (1994).
47. Lecker, S. H. et al. Ubiquitin conjugation by the N-end rule pathway and mRNAs for its components increase in muscles of diabetic rats. J. Clin. Invest. 104, 1411-1420 (1999).
48. Attaix, D., Combaret, L., Pouch, M. N. & Taillandier, D. Regulation of proteolysis. Curr. Opin. Clin. Nutr. Metab. Care 4, 45-9 (2001).
49. Gomes, M. D., Lecker, S. H., Jagoe, R. T., Navon, A. & Goldberg, A. L. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc. Natl Acad. Sci. USA 98, 14440-14445 (2001).
50. Bodine, S. C. et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294, 1704-1708 (2001).
51. Centner, T. et al. Identification of muscle specific ring finger proteins as potential regulators of the titin kinase domain. J. Mol. Biol. 306, 717-726 (2001).
52. McElhinny, A. S., Kakinuma, K., Sorimachi, H., Labeit, S. & Gregorio, C. C. Muscle-specific RING finger-1 interacts with titin to regulate sarcomeric M-line and thick filament structure and may have nuclear functions via its interaction with glucocorticoid modulatory element binding protein-1. J. Cell Biol. 157, 125-136 (2002).